McColl Partners, LLC acted as financial advisor to Zymed Laboratories, Inc. ("Zymed") in its $60 million sale to Invitrogen Corporation ("Invitrogen") (Nasdaq:IVGN), a leading, global life sciences company.

The acquisition provides Invitrogen with more than 2,000 antibodies and related products that match key areas of its research product focus, including cancer, neurological, and infectious diseases.  Combining Zymed's extensive experience in antibody design, development, modification, purification, and production with Invitrogen's broad portfolio of technologies and reagents will provide researchers and clinical laboratories with a consistent, comprehensive system to accelerate scientific discovery.

About Zymed Laboratories, Inc.

Zymed is an integrated, technology-driven, immunoassay reagent company based in South San Francisco, California.  Zymed serves two primary segments: life sciences research and clinical diagnostics.  Zymed has over 21 years of technological expertise in antibody design, development, modification, purification, and production.

About McColl Partners, LLC

McColl Partners is an independent investment banking firm specializing in the needs of management and owners of middle-market companies.  With significant experience working with private equity groups, entrepreneurs, family-owned businesses, public companies, financial institutions, and divisions of large companies, the firm is dedicated to offering strategic advice and assistance to its clients regarding mergers and acquisitions and private capital raising assignments.

For more information about our Healthcare Group, please contact Dave Vorhoff or Brian Davis at (704) 333-0525.  More information about McColl Partners can be found at www.mccollpartners.com.